Cargando…

Effect of Metformin on Doxorubicin-Induced Memory Dysfunction

Doxorubicin (DOX) is widely used to treat many types of cancer; however, it is associated with chemotherapy-related complications such as cognitive dysfunction, known as chemobrain. Chemobrain affects up to 75% of cancer survivors, and there are currently no available therapeutic options. This study...

Descripción completa

Detalles Bibliográficos
Autores principales: Alharbi, Ibrahim, Alharbi, Hindi, Almogbel, Yasser, Alalwan, Abdullah, Alhowail, Ahmad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139300/
https://www.ncbi.nlm.nih.gov/pubmed/32156040
http://dx.doi.org/10.3390/brainsci10030152
_version_ 1783518734032306176
author Alharbi, Ibrahim
Alharbi, Hindi
Almogbel, Yasser
Alalwan, Abdullah
Alhowail, Ahmad
author_facet Alharbi, Ibrahim
Alharbi, Hindi
Almogbel, Yasser
Alalwan, Abdullah
Alhowail, Ahmad
author_sort Alharbi, Ibrahim
collection PubMed
description Doxorubicin (DOX) is widely used to treat many types of cancer; however, it is associated with chemotherapy-related complications such as cognitive dysfunction, known as chemobrain. Chemobrain affects up to 75% of cancer survivors, and there are currently no available therapeutic options. This study aims to examine whether metformin (MET) can protect against the neurotoxicity caused by DOX treatment. Forty male rats were divided into four groups (10 rats/group): control, DOX, DOX + MET, and MET. Rats treated with DOX received five doses of 4 mg/kg DOX weekly (cumulative dose: 20 mg/kg). For the DOX-MET and MET groups, MET (3 mg/mL) was dissolved in drinking water. Behavioral and glucose tests were performed one day after treatment was completed. We found DOX (4 mg/kg/week, 5 weeks) caused learning and memory impairment in the Y-maze, novel object recognition, and elevated plus maze behavioral tests. MET did not rescue these DOX-induced memory impairments. Neither DOX nor MET nor MET + DOX altered glucose levels following the treatment. In summary, DOX treatment is associated with memory impairment in rats, but MET does not rescue this cognitive dysfunction.
format Online
Article
Text
id pubmed-7139300
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-71393002020-04-10 Effect of Metformin on Doxorubicin-Induced Memory Dysfunction Alharbi, Ibrahim Alharbi, Hindi Almogbel, Yasser Alalwan, Abdullah Alhowail, Ahmad Brain Sci Article Doxorubicin (DOX) is widely used to treat many types of cancer; however, it is associated with chemotherapy-related complications such as cognitive dysfunction, known as chemobrain. Chemobrain affects up to 75% of cancer survivors, and there are currently no available therapeutic options. This study aims to examine whether metformin (MET) can protect against the neurotoxicity caused by DOX treatment. Forty male rats were divided into four groups (10 rats/group): control, DOX, DOX + MET, and MET. Rats treated with DOX received five doses of 4 mg/kg DOX weekly (cumulative dose: 20 mg/kg). For the DOX-MET and MET groups, MET (3 mg/mL) was dissolved in drinking water. Behavioral and glucose tests were performed one day after treatment was completed. We found DOX (4 mg/kg/week, 5 weeks) caused learning and memory impairment in the Y-maze, novel object recognition, and elevated plus maze behavioral tests. MET did not rescue these DOX-induced memory impairments. Neither DOX nor MET nor MET + DOX altered glucose levels following the treatment. In summary, DOX treatment is associated with memory impairment in rats, but MET does not rescue this cognitive dysfunction. MDPI 2020-03-07 /pmc/articles/PMC7139300/ /pubmed/32156040 http://dx.doi.org/10.3390/brainsci10030152 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Alharbi, Ibrahim
Alharbi, Hindi
Almogbel, Yasser
Alalwan, Abdullah
Alhowail, Ahmad
Effect of Metformin on Doxorubicin-Induced Memory Dysfunction
title Effect of Metformin on Doxorubicin-Induced Memory Dysfunction
title_full Effect of Metformin on Doxorubicin-Induced Memory Dysfunction
title_fullStr Effect of Metformin on Doxorubicin-Induced Memory Dysfunction
title_full_unstemmed Effect of Metformin on Doxorubicin-Induced Memory Dysfunction
title_short Effect of Metformin on Doxorubicin-Induced Memory Dysfunction
title_sort effect of metformin on doxorubicin-induced memory dysfunction
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139300/
https://www.ncbi.nlm.nih.gov/pubmed/32156040
http://dx.doi.org/10.3390/brainsci10030152
work_keys_str_mv AT alharbiibrahim effectofmetforminondoxorubicininducedmemorydysfunction
AT alharbihindi effectofmetforminondoxorubicininducedmemorydysfunction
AT almogbelyasser effectofmetforminondoxorubicininducedmemorydysfunction
AT alalwanabdullah effectofmetforminondoxorubicininducedmemorydysfunction
AT alhowailahmad effectofmetforminondoxorubicininducedmemorydysfunction